Subscribe To
Biovaxys says studies on bvx-0320, its haptenized sars-cov-2 s-spike protein vaccine, suggest superior cardiac safety
BioVaxys Technology Corp has revealed that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine candidate, demonstrated that the va...
February 16, 2022, 9:48 am
Fda slams brakes on legend biotech's car-t therapy trial in lymphoma patients
The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's investig...
February 15, 2022, 9:39 am
Fda slams brakes on legend biotech's car-t therapy trial in lymphoma patients
The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's investig...
February 15, 2022, 9:39 am
Fda slams brakes on legend biotech's car-t therapy trial in lymphoma patients
The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's investig...
February 15, 2022, 9:39 am
Avalon globocare adds car-nk cell therapies to expand cellular immuno-oncology platform
Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen ...
February 14, 2022, 11:57 am
Avalon globocare adds car-nk cell therapies to expand cellular immuno-oncology platform
Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen ...
February 14, 2022, 11:57 am
Avalon globocare adds car-nk cell therapies to expand cellular immuno-oncology platform
Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen ...
February 14, 2022, 11:57 am
Avalon globocare expands its cellular immuno-oncology program with addition of chimeric antigen receptor-natural killer cell therapies
Avalon GloboCare Corp (NASDAQ:AVCO) said it is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen ...
February 14, 2022, 10:21 am
Avalon globocare expands its cellular immuno-oncology program with addition of chimeric antigen receptor-natural killer cell therapies
Avalon GloboCare Corp (NASDAQ:AVCO) said it is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen ...
February 14, 2022, 10:21 am
Avalon globocare expands its cellular immuno-oncology program with addition of chimeric antigen receptor-natural killer cell therapies
Avalon GloboCare Corp (NASDAQ:AVCO) said it is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen ...
February 14, 2022, 10:21 am
Psyched wellness reports additional positive results from preclinical oral toxicity study of amanita muscaria (ame-1)
Psyched Wellness Ltd reported additional positive findings from the preclinical 14-day oral toxicity study with Amanita Muscaria (AME-1), which was pe...
February 3, 2022, 9:08 am
Psyched wellness reports additional positive results from preclinical oral toxicity study of amanita muscaria (ame-1)
Psyched Wellness Ltd reported additional positive findings from the preclinical 14-day oral toxicity study with Amanita Muscaria (AME-1), which was pe...
February 3, 2022, 9:08 am
Psyched wellness reports additional positive results from preclinical oral toxicity study of amanita muscaria (ame-1)
Psyched Wellness Ltd reported additional positive findings from the preclinical 14-day oral toxicity study with Amanita Muscaria (AME-1), which was pe...
February 3, 2022, 9:08 am
Mindset pharma identifies additional drug candidates from 'family 3' compounds
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has synthesized additional promising candidates from its Family 3 of next-generation drug...
February 3, 2022, 8:49 am
Mindset pharma identifies additional drug candidates from 'family 3' compounds
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has synthesized additional promising candidates from its Family 3 of next-generation drug...
February 3, 2022, 8:49 am
Mindset pharma identifies additional drug candidates from 'family 3' compounds
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has synthesized additional promising candidates from its Family 3 of next-generation drug...
February 3, 2022, 8:49 am
Celyad oncology announces february 2022 conference schedule
MONT-SAINT-GUIBERT, Belgium, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company fo...
January 31, 2022, 4:05 pm
Celyad oncology announces february 2022 conference schedule
MONT-SAINT-GUIBERT, Belgium, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company fo...
January 31, 2022, 4:05 pm
Celyad oncology announces february 2022 conference schedule
MONT-SAINT-GUIBERT, Belgium, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company fo...
January 31, 2022, 4:05 pm
Fda clears lyell immunopharma' lyl132 trial for solid tumors
The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in so...
January 24, 2022, 12:39 pm